# CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Study · id `cardio:ct-nct05681351` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05681351](<https://clinicaltrials.gov/study/NCT05681351>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05681351

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 885 participants.

## Technical summary

Registry record NCT05681351. Allocation not applicable; no masking; primary purpose treatment. Start 2022-12-13 (actual); primary completion 2027-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 885 participants (enrolled count; ClinicalTrials.gov record NCT05681351, source copy `cardio:ctgov-nct05681351-2025-12-01`, retrieved 2026-10-31)
- Started: 2022-12-13 (actual) (ClinicalTrials.gov record NCT05681351, source copy `cardio:ctgov-nct05681351-2025-12-01`, retrieved 2026-10-31)
- Primary completion: 2027-03 (anticipated) (ClinicalTrials.gov record NCT05681351, source copy `cardio:ctgov-nct05681351-2025-12-01`, retrieved 2026-10-31)
- Completion: 2027-03 (anticipated) (ClinicalTrials.gov record NCT05681351, source copy `cardio:ctgov-nct05681351-2025-12-01`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Czechia; Denmark; Finland; France; Germany; Greece; Hungary; India; Israel; Italy; Lithuania; Malaysia; Mexico; Netherlands; New Zealand; Norway; Poland; Portugal; Romania; Slovakia; South Africa; Spain; Sweden; Taiwan; Türkiye; United Kingdom (ClinicalTrials.gov record NCT05681351, source copy `cardio:ctgov-nct05681351-2025-12-01`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05681351-2025-12-01`, retrieved 2026-10-31)

## The registry's words

- Brief title: CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
- Condition: Severe Hypertriglyceridemia
- Intervention (Drug): Olezarsen
- Lead sponsor: Ionis Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Ionis Pharmaceuticals, Inc. (`cardio:org-ionis-pharmaceuticals-inc`)

## Provenance

Content hash: ab3340695f5706ef09aea2edf21e27513a0a29e3c1cc1fccf393141762dfe694
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
